The vast majority of localized and metastatic prostate carcinomas depend on androgenic hormones and signaling through the androgen receptor (AR) to maintain survival and growth, a feature that has served as a therapeutic focal point for more than 70 years (2, 3). The gene discussed is AR; the disease is prostate carcinoma.